IRD
Opus Genetics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.67
+1.52%Year over year
Reported trailing growth
- Revenue
- -36.1%
- EBITDA
- —
- EBIT
- +22.0%
- EPS
- +27.8%
- Free cash flow
- -27.8%
- Operating cash flow
- -27.8%
Forward estimates
Based on analyst estimates
- Revenue
- +24.3%
- EBITDA
- +43.9%
- EPS
- +55.9%
Three-year CAGR
- Revenue
- -29.1%
- EBITDA
- +16.4%
- EBIT
- +37.8%
- Net income
- +13.8%
- EPS
- +62.8%
- Free cash flow
- -37.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026